|
1
|
Hankinson O: The aryl hydrocarbon receptor
complex. Annu Rev Pharmacol Toxicol. 35:307–340. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hankinson O: Role of coactivators in
transcriptional activation by the aryl hydrocarbon receptor. Arch
Biochem Biophys. 433:379–386. 2005. View Article : Google Scholar
|
|
3
|
Kamenickova A, Anzenbacherova E, Pavek P,
Soshilov AA, Denison MS, Anzenbacher P and Dvorak Z: Pelargonidin
activates the AhR and induces CYP1A1 in primary human hepatocytes
and human cancer cell lines HepG2 and LS174T. Toxicol Lett.
218:253–259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamenickova A, Anzenbacherova E, Pavek P,
Soshilov AA, Denison MS, Zapletalova M, Anzenbacher P and Dvorak Z:
Effects of anthocyanins on the AhR-CYP1A1 signaling pathway in
human hepatocytes and human cancer cell lines. Toxicol Lett.
221:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dvorak Z, Vrzal R, Henklova P, Jancova P,
Anzenbacherova E, Maurel P, Svecova L, Pavek P, Ehrmann J, Havlik
R, et al: JNK inhibitor SP600125 is a partial agonist of human aryl
hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary
human hepatocytes. Biochem Pharmacol. 75:580–588. 2008. View Article : Google Scholar
|
|
6
|
Pastorková B, Vrzalová A, Bachleda P and
Dvořák Z: Hydroxystilbenes and methoxystilbenes activate human aryl
hydrocarbon receptor and induce CYP1A genes in human hepatoma cells
and human hepatocytes. Food Chem Toxicol. 103:122–132. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Palermo CM, Hernando JI, Dertinger SD,
Kende AS and Gasiewicz TA: Identification of potential aryl
hydrocarbon receptor antagonists in green tea. Chem Res Toxicol.
16:865–872. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Go RE, Hwang KA and Choi KC: Cytochrome
P450 1 family and cancers. J Steroid Biochem Mol Biol. 147:24–30.
2015. View Article : Google Scholar
|
|
9
|
Stejskalova L and Pavek P: The function of
cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor
(AhR) in the placenta. Curr Pharm Biotechnol. 12:715–730. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Forrester AR, Elias MS, Woodward EL,
Graham M, Williams FM and Reynolds NJ: Induction of a chloracne
phenotype in an epidermal equivalent model by
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is dependent on aryl
hydrocarbon receptor activation and is not reproduced by aryl
hydrocarbon receptor knock down. J Dermatol Sci. 73:10–22. 2014.
View Article : Google Scholar :
|
|
11
|
Pierre S, Chevallier A, Teixeira-Clerc F,
Ambolet-Camoit A, Bui LC, Bats AS, Fournet JC, Fernandez-Salguero
P, Aggerbeck M, Lotersztajn S, et al: Aryl hydrocarbon
receptor-dependent induction of liver fibrosis by dioxin. Toxicol
Sci. 137:114–124. 2014. View Article : Google Scholar
|
|
12
|
Wu D, Nishimura N, Kuo V, Fiehn O, Shahbaz
S, Van Winkle L, Matsumura F and Vogel CF: Activation of aryl
hydrocarbon receptor induces vascular inflammation and promotes
atherosclerosis in apolipoprotein E−/− mice.
Arterioscler Thromb Vasc Biol. 31:1260–1267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roh E, Kwak SH, Jung HS, Cho YM, Pak YK,
Park KS, Kim SY and Lee HK: Serum aryl hydrocarbon receptor ligand
activity is associated with insulin resistance and resulting type 2
diabetes. Acta Diabetol. 52:489–495. 2015. View Article : Google Scholar
|
|
14
|
Brito JS, Borges NA, Esgalhado M, Magliano
DC, Soulage CO and Mafra D: Aryl hydrocarbon receptor activation in
chronic kidney disease: Role of uremic toxins. Nephron. 137:1–7.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esser C: The aryl hydrocarbon receptor in
immunity: Tools and potential. Methods Mol Biol. 1371:239–257.
2016. View Article : Google Scholar
|
|
16
|
Murray IA, Patterson AD and Perdew GH:
Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat
Rev Cancer. 14:801–814. 2014. View
Article : Google Scholar
|
|
17
|
Nukaya M, Moran S and Bradfield CA: The
role of the dioxin-responsive element cluster between the Cyp1a1
and Cyp1a2 loci in aryl hydrocarbon receptor biology. Proc Natl
Acad Sci USA. 106:4923–4928. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uno S, Dalton TP, Sinclair PR, Gorman N,
Wang B, Smith AG, Miller MI, Shertzer HG and Nebert DW: Cyp1a1(−/−)
male mice: Protection against high-dose TCDD-induced lethality and
wasting syndrome, and resistance to intrahepatocyte lipid
accumulation and uroporphyria. Toxicol Appl Pharmacol. 196:410–421.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singh KP, Garrett RW, Casado FL and
Gasiewicz TA: Aryl hydrocarbon receptor-null allele mice have
hematopoietic stem/progenitor cells with abnormal characteristics
and functions. Stem Cells Dev. 20:769–784. 2011. View Article : Google Scholar :
|
|
20
|
Barouki R, Coumoul X and
Fernandez-Salguero PM: The aryl hydrocarbon receptor, more than a
xenobiotic-interacting protein. FEBS Lett. 581:3608–3615. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mulero-Navarro S and Fernandez-Salguero
PM: New trends in aryl hydrocarbon receptor biology. Front Cell Dev
Biol. 4:452016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moennikes O, Loeppen S, Buchmann A,
Andersson P, Ittrich C, Poellinger L and Schwarz M: A
constitutively active dioxin/aryl hydrocarbon receptor promotes
hepatocarcinogenesis in mice. Cancer Res. 64:4707–4710. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan Y, Boivin GP, Knudsen ES, Nebert DW,
Xia Y and Puga A: The aryl hydrocarbon receptor functions as a
tumor suppressor of liver carcinogenesis. Cancer Res. 70:212–220.
2010. View Article : Google Scholar
|
|
24
|
Corchero J, Martín-Partido G, Dallas SL
and Fernández-Salguero PM: Liver portal fibrosis in dioxin
receptor-null mice that overexpress the latent transforming growth
factor-beta-binding protein-1. Int J Exp Pathol. 85:295–302. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schmidt JV, Su GH-T, Reddy JK, Simon MC
and Bradfield CA: Characterization of a murine Ahr null allele:
Involvement of the Ah receptor in hepatic growth and development.
Proc Natl Acad Sci USA. 93:6731–6736. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lahvis GP, Lindell SL, Thomas RS, McCuskey
RS, Murphy C, Glover E, Bentz M, Southard J and Bradfield CA:
Portosystemic shunting and persistent fetal vascular structures in
aryl hydrocarbon receptor-deficient mice. Proc Natl Acad Sci USA.
97:10442–10447. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jackson DP, Li H, Mitchell KA, Joshi AD
and Elferink CJ: Ah receptor-mediated suppression of liver
regeneration through NC-XRE-driven p21Cip1 expression. Mol
Pharmacol. 85:533–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mathew LK, Simonich MT and Tanguay RL:
AHR-dependent misregulation of Wnt signaling disrupts tissue
regeneration. Biochem Pharmacol. 77:498–507. 2009. View Article : Google Scholar :
|
|
29
|
Moreno-Marín N, Barrasa E,
Morales-Hernández A, Paniagua B, Blanco-Fernández G, Merino JM and
Fernández-Salguero PM: Dioxin receptor adjust liver regeneration
after acute toxic injury and protects against liver carcinogenesis.
Sci Rep. 7:104202017. View Article : Google Scholar
|
|
30
|
Knowles BB, Howe CC and Aden DP: Human
hepatocellular carcinoma cell lines secrete the major plasma
proteins and hepatitis B surface antigen. Science. 209:497–499.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choi EY, Lee H, Dingle RWC, Kim KB and
Swanson HI: Development of novel CH223191-based antagonists of the
aryl hydrocarbon receptor. Mol Pharmacol. 81:3–11. 2012. View Article : Google Scholar :
|
|
32
|
Fang Z, Tang Y, Fang J, Zhou Z, Xing Z,
Guo Z, Guo X, Wang W, Jiao W, Xu Z and Liu Z: See comment in PubMed
Commons belowSimvastatin inhibits renal cancer cell growth and
metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One.
8:e628232013. View Article : Google Scholar
|
|
33
|
Wang K, Li Y, Jiang YZ, Dai CF, Patankar
MS, Song JS and Zheng J: An endogenous aryl hydrocarbon receptor
ligand inhibits proliferation and migration of human ovarian cancer
cells. Cancer Lett. 340:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamaguchi M and Daimon Y: Overexpression
of regucalcin suppresses cell proliferation in cloned rat hepatoma
H4-II-E cells: Involvement of intracellular signaling factors and
cell cycle-related genes. J Cell Biochem. 95:1169–1177. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Izumi T and Yamaguchi M: Overexpression of
regucalcin suppresses cell death in cloned rat hepatoma H4-II-E
cells induced by tumor necrosis factor-alpha or thapsigargin. J
Cell Biochem. 92:296–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamaguchi M, Osuka S, Weitzmann MN,
El-Rayes BF, Shoji M and Murata T: Prolonged survival in pancreatic
cancer patients with increased regucalcin gene expression:
Overexpression of regucalcin suppresses the proliferation in human
pancreatic cancer MIA PaCa-2 cells in vitro. Int J Oncol.
48:1955–1964. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamaguchi M and Isogai M: Tissue
concentration of calcium-binding protein regucalcin in rats by
enzyme-linked immunoadsorbent assay. Mol Cell Biochem. 122:65–68.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vaziri C, Schneider A, Sherr DH and Faller
DV: Expression of AHR is regulated by serum and mitogenic growth
factors in murine 3T3 fibroblasts. J Biol Chem. 271:25921–25927.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Umannová L, Zatloukalová J, Machala M,
Krcmár P, Májková Z, Hennig B, Kozubík A and Vondrácek J: Tumor
necrosis factor-α modulates effects of aryl hydrocarbon receptor
ligands on cell proliferation and expression of cytochrome P450
enzymes in rat liver 'stem-like' cells. Toxicol Sci. 99:79–89.
2007. View Article : Google Scholar
|
|
40
|
Tsurusaki Y and Yamaguchi M: Role of
regucalcin in liver nuclear function: Binding of regucalcin to
nuclear protein or DNA and modulation of tumor-related gene
expression. Int J Mol Med. 14:277–281. 2004.PubMed/NCBI
|
|
41
|
Yamaguchi M: Suppressive role of
regucalcin in liver cell proliferation: Involvement in
carcinogenesis. Cell Prolif. 46:243–253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tang SC and Chen YC: Novel therapeutic
targets for pancreatic cancer. World J Gastroenterol.
20:10825–10844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vogel CFA, Wu D, Goth SR, Baek J, Lollies
A, Domhardt R, Grindel A and Pessah IN: Aryl hydrocarbon receptor
signaling regulates NF-κB RelB activation during dendritic-cell
differentiation. Immunol Cell Biol. 91:568–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han M, Liu X, Liu S, Su G, Fan X, Chen J,
Yuan Q and Xu G: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces
hepatic stellate cell (HSC) activation and liver fibrosis in C57BL6
mouse via activating Akt and NF-κB signaling pathways. Toxicol
Lett. 273:10–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jennen D, Ruiz-Aracama A, Magkoufopoulou
C, Peijnenburg A, Lommen A, van Delft J and Kleinjans J:
Integrating transcriptomics and metabonomics to unravel
modes-of-action of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in
HepG2 cells. BMC Syst Biol. 5:1392011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nejak-Bowen KN, Zeng G, Tan X, Cieply B
and Monga SP: Beta-catenin regulates vitamin C biosynthesis and
cell survival in murine liver. J Biol Chem. 284:28115–28127. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yamaguchi M, Osuka S, Weitzmann MN,
El-Rayes BF, Shoji M and Murata T: Prolonged survival in
hepatocarcinoma patients with increased regucalcin gene expression:
HepG2 cell proliferation is suppressed by overexpression of
regucalcin in vitro. Int J Oncol. 49:1686–1694. 2016. View Article : Google Scholar : PubMed/NCBI
|
